High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib

Participation Requirements

• Sex:

  ALL

• Eligible Ages:

  19 and up

Participation Criteria

Inclusion Criteria:

* Age 19 years or older
* Idiopathic Pulmonary Fibrosis (IPF) diagnosis according to American Thoracic Society and/or European Respiratory Society consensus criteria
* Appropriate candidate for pulmonary rehabilitation
* prescribed nintedanib by their treating physician or currently on nintedanib
* 6 minute walk distance 50m or more
* Oxygen saturation 92% or more by pulse oximetry at rest while breathing room air
* Clinically stable for the preceding 6 weeks

Exclusion Criteria:

* Contraindication to treatment with nintedanib (based on Canadian labeling)
* Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease)
* Other significant extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and/or oxygenation
* Forced vital capacity (FVC) less than 50% or Diffusion capacity for carbon monoxide (DLCO) less than 25%
* Concurrent or recent participation (less than 6 months) in a pulmonary rehabilitation program
* Use of prednisone greater than 10 mg/day for more than 2 weeks within 3 months of the first study visit
* Use of pirfenidone within 4 weeks of screening
* Significant emphysema (less than 10% volume on high resolution computed tomography (HRCT) or forced expiratory volume at one second (FEV1)/FVC less than 0.70)